Medicare Coverage for Cologuard Testing
Medicare Part B covers Cologuard (multitarget stool DNA test) once every 3 years for average-risk beneficiaries aged 50-85 years who meet specific criteria.
Coverage Frequency and Eligibility
Medicare follows the 3-year screening interval for Cologuard testing, which aligns with major clinical guidelines 1, 2, 3. This is the standard recommended frequency for multitarget stool DNA testing (mt-sDNA) across all major professional societies.
Specific Coverage Criteria:
- Age range: 50-85 years (though recent guidelines now recommend starting at age 45, Medicare coverage traditionally begins at 50)
- Risk status: Average-risk individuals only
- Interval: Once every 3 years
- Exclusions: Not covered for individuals with:
- Personal history of colorectal cancer or adenomatous polyps
- Personal history of inflammatory bowel disease
- Family history of colorectal cancer or hereditary syndromes (Lynch syndrome, familial adenomatous polyposis)
- Prior abdominal/pelvic radiation
Important Coverage Considerations
Follow-up colonoscopy after positive results is covered separately and does not count against the 3-year screening interval. If Cologuard returns positive, Medicare will cover the diagnostic colonoscopy needed to complete the screening process 1, 2.
Age-Specific Guidance:
- Ages 50-75: Strong recommendation for regular screening; Medicare covers without restrictions 2, 3
- Ages 76-85: Coverage continues but should be individualized based on life expectancy >10 years, health status, and prior screening history 2, 3
- Over age 85: Screening generally discouraged; Medicare may not routinely cover 2, 3
Clinical Context
The 3-year interval for Cologuard is based on its test characteristics—higher sensitivity for colorectal cancer (approximately 92%) but moderate sensitivity for advanced precancerous lesions (42-69%) 4. This differs from annual fecal immunochemical testing (FIT), which Medicare also covers yearly as an alternative stool-based option 1, 2.
Key caveat: Real-world Medicare data shows completion rates around 75.8% for mt-sDNA testing, with higher completion among traditional Medicare versus Medicare Advantage beneficiaries (81.7% vs 71.7%) 5. Utilization has increased dramatically since 2014 approval, with compound annual growth rate of 166.81% through 2018 6.
Alternative Covered Options:
If a patient prefers different screening intervals, Medicare also covers:
- Annual FIT or high-sensitivity guaiac-based fecal occult blood test 1, 2
- Colonoscopy every 10 years 1, 2
- Flexible sigmoidoscopy every 5 years 1, 2
- CT colonography every 5 years 1, 2
The choice among these options should be based on patient preference and access, as adherence is the most critical factor for screening effectiveness 1, 7.